ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026
Peripheral immune checkpoint gene expression as diagnostic biomarkers in idiopathic pulmonary fibrosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimIdiopathic pulmonary fibrosis (IPF) is a relatively rare and progressive fibrotic interstitial lung disease with limited annual incidence and poor prognosis. Increasing evidence suggests that immune dysregulation, including altered immune checkpoint and innate regulatory signaling pathways, may contribute to disease pathogenesis. This study aimed to investigate peripheral blood expression levels of PD-1, PD-L1, TIM-3, and TOLLIP genes and to evaluate their diagnostic potential in patients with IPF.
methodsThis case-control study included 20 IPF patients and 20 age-matched healthy controls. Gene expression levels were quantified using real-time quantitative polymerase chain reaction (RT-qPCR) and calculated using the ΔCt method. Diagnostic discrimination was assessed by receiver operating characteristic (ROC) analysis.
resultsPD-L1 (p < 0.001) and TOLLIP (p = 0.002) ΔCt values were significantly higher, indicating reduced relative gene expression. ROC analysis demonstrated strong diagnostic performance for PD-L1 (AUC = 0.883) and TOLLIP (AUC = 0.865). The combined PD-L1 + TOLLIP biomarker panel demonstrated superior diagnostic accuracy (AUC = 0.948). Internal validation using bootstrap resampling confirmed model stability (mean AUC = 0.950; 95% CI: 0.85-1.00).
conclusionsIn conclusion, peripheral blood PD-L1 and TOLLIP expression levels are significantly downregulated in patients with idiopathic pulmonary fibrosis. The combined PD-L1 + TOLLIP biomarker panel demonstrated strong diagnostic discrimination (AUC = 0.948), supporting the potential clinical utility of peripheral immune regulatory gene signatures as minimally invasive biomarkers in IPF. Larger prospective studies are warranted to validate these findings and to explore their potential role in clinical decision-making.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.